1. Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
- Author
-
Vicky Makker, Jason A. Konner, Maria M. Rubinstein, Kay J. Park, and Sherry Shen
- Subjects
Mesonephric-like ,endocrine system diseases ,education ,Pembrolizumab ,medicine.disease_cause ,Mesonephric duct ,chemistry.chemical_compound ,Case Reports and Case Series ,KRAS ,medicine ,Lenvatinib ,In patient ,neoplasms ,RC254-282 ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Obstetrics and Gynecology ,Gynecology and obstetrics ,medicine.disease ,digestive system diseases ,respiratory tract diseases ,Oncology ,chemistry ,Sustained response ,RG1-991 ,Cancer research ,Adenocarcinoma ,Mesonephric ,business ,Endometrial - Abstract
Highlights • Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pembrolizumab. • Tumors with KRAS mutations may be particularly sensitive to lenvatinib, but this warrants further study.
- Published
- 2021
- Full Text
- View/download PDF